What is the role of N-acetyl cysteine (NAC) in treating paracetamol (acetaminophen) poisoning?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

N-Acetylcysteine in Paracetamol Poisoning

N-acetylcysteine (NAC) is the only proven antidote for paracetamol poisoning and must be administered immediately when overdose is suspected—ideally within 8 hours of ingestion—to prevent hepatotoxicity and death. 1, 2

Critical Timing: The 8-Hour Window

The efficacy of NAC is dramatically time-dependent, creating distinct treatment windows:

  • Within 8 hours: Only 2.9% develop severe hepatotoxicity—this represents near-complete protection 1, 2
  • 8-10 hours: Severe hepatotoxicity increases to 6.1% 1, 2
  • 10-24 hours: Severe hepatotoxicity jumps to 26.4% 1, 2
  • After 24 hours: NAC still provides benefit and reduces mortality, though efficacy is significantly diminished 2, 3

NAC should never be withheld regardless of presentation time—even in established hepatic failure, it reduces mortality from 80% to 52% 1, 2

When to Administer NAC: Decision Algorithm

Immediate Treatment Required (Do Not Wait for Labs):

  • Serum paracetamol level plots above the treatment line on the Rumack-Matthew nomogram (drawn 4-24 hours post-ingestion) 1, 2
  • Unknown time of ingestion with detectable paracetamol levels 1, 2
  • Established hepatic failure with suspected paracetamol ingestion, even without confirmatory history 1, 2
  • Very high aminotransferases (AST/ALT >3,500 IU/L), which are highly correlated with paracetamol poisoning 1
  • Any elevation in AST or ALT with suspected overdose 2

Special High-Risk Populations (Lower Treatment Threshold):

  • Chronic alcohol users: Treat even with levels in the "non-toxic" range—severe hepatotoxicity documented with doses as low as 4-5 g/day 1, 2
  • Prolonged fasting or malnutrition 1
  • Enzyme-inducing drugs 2

NAC Dosing Regimens

Intravenous Protocol (21-hour regimen):

  • Loading dose: 150 mg/kg in 5% dextrose over 15 minutes 1, 3
  • Second dose: 50 mg/kg over 4 hours 1
  • Third dose: 100 mg/kg over 16 hours 1

Oral Protocol (72-hour regimen):

  • Loading dose: 140 mg/kg orally or via nasogastric tube 1
  • Maintenance: 70 mg/kg every 4 hours for 17 additional doses 1

The oral 72-hour protocol may be superior to the 21-hour IV regimen when treatment is delayed, as modeling studies suggest the 21-hour infusion is often too short 2, 4

Adjunctive Management

  • Activated charcoal (1 g/kg) should be given just prior to starting NAC if patient presents within 4 hours of ingestion 1, 2
  • Do not delay NAC even if activated charcoal has been given 1

Special Clinical Scenarios Requiring Extended Treatment

Continue NAC beyond standard protocol for:

  • Delayed presentation (>24 hours post-ingestion) 2
  • Extended-release paracetamol formulations (prolonged absorption requires extended monitoring) 1, 2
  • Repeated supratherapeutic ingestions 1, 2
  • Unknown time of ingestion with detectable levels 2
  • Any elevation in transaminases 2

When to Stop NAC

NAC can be discontinued only when ALL of the following criteria are met:

  • Paracetamol level is undetectable 2
  • AST and ALT remain completely normal (no elevation above normal) 2
  • No coagulopathy 2
  • No clinical signs of hepatotoxicity 2

Critical Red Flags—Continue or Restart NAC Immediately:

  • Any elevation in AST or ALT above normal 2
  • Rising transaminases 2
  • Any coagulopathy 2
  • Detectable paracetamol level 2

Critical Pitfalls to Avoid

  • The Rumack-Matthew nomogram does NOT apply to presentations >24 hours post-ingestion, repeated supratherapeutic ingestions, or extended-release formulations 2
  • Low or absent paracetamol levels do NOT rule out poisoning if ingestion was remote or occurred over several days 2
  • Never delay NAC while awaiting confirmatory levels if there is strong suspicion of significant overdose 1
  • Extended-release formulations may show late increases in serum paracetamol at 14 hours or beyond—obtain serial levels 2

Severe Hepatotoxicity Management

For patients with AST/ALT >1,000 IU/L or coagulopathy:

  • Restart or continue NAC immediately 2
  • Require ICU-level care 2
  • Contact liver transplant center immediately 2
  • Continue NAC until transaminases are declining and INR normalizes 2

Adverse Effects

  • IV route: Anaphylactic reactions and cutaneous adverse events are most common 5
  • Oral route: Gastrointestinal adverse events predominate 5

References

Guideline

N-Acetylcysteine Administration in Acetaminophen Overdose

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Acetaminophen Overdose Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the preferred route of administration for N-acetylcysteine (NAC) in treating acetaminophen overdose, intravenous (IV) or oral?
What is the treatment guideline for a 14-year-old patient who has taken an overdose of 24 Dolo (paracetamol) tablets, is stable, but complains of stomach ache?
What is the treatment for a patient with a paracetamol (acetaminophen) overdose to protect the liver?
What is the administration protocol for N-acetylcysteine (NAC) in a patient with acetaminophen (paracetamol) overdose?
How to initiate N-acetylcysteine (NAC) therapy in patients with Acute Liver Failure (ALF), particularly those with suspected acetaminophen overdose?
A 37-year-old nulligravid woman taking Yaz (drospirenone and ethinyl estradiol) for years with oligomenorrhea wants to conceive, what steps should she take?
Can a nontender cervical lump and apathy be signs of a systemic infection or autoimmune disorder?
Why does the White Blood Cell (WBC) count increase during an episode of Gastroesophageal Reflux Disease (GERD) in adults?
What is the significance and management of arthralgia in a patient suspected of having Kawasaki disease, characterized by a nontender cervical lump and apathy?
What is the appropriate evaluation and management approach for a patient presenting with dizziness, considering their demographic, medical history, and potential underlying conditions?
Do you treat Vancomycin-resistant Enterococcus faecium in a urine culture with 10,000 to 49,000 CFU in an adult patient with a compromised immune system or underlying medical conditions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.